|
|
Intravitreal Injection of Conbercept Combined with Ahemd Glaucoma Valve Implants and Panretinal Photocoagulation Treatment for Neovascular Glaucoma |
Ou Hai, Fang Liu, Danyu Gao |
The Number 986 Hospital of the Air Force, Xi'an 710018, China |
|
|
Abstract Objective: To observe the clinical effects of intravitreal injection of conbercept combined with Ahemd glaucoma valve implant and panretinal photocoagulation treatment for neovascular glaucoma (NVG). Methods: In this retrospective case series study, 16 NVG patients (17 eyes), at the Number 986 Hospital of the Air Force, were treated from June, 2017 to June, 2018 with intravitreal injection of conbercept combined with Ahemd glaucoma valve implants and panretinal photocoagulation. The disappearance of neovascularization, intraocular pressure (IOP) and best corrected visual acuity (BCVA) were compared between preoperative and postoperative conditions. The data were analyzed by repeated measures ANOVA. The IOP between preoperative and every follow-up was analyzed with independent sample t test. Results: After injection, neovascularization was greatly diminshed by 3 d, and completely vanished by 1 month. The preoperative IOP was 43.3±7.6 mmHg, and postoperative IOP was 14.8±4.8 mmHg, 13.7± 3.9 mmHg, 14.5±4.6 mmHg, 13.6±5.4 mmHg and 13.9±4.6 mmHg at 3 d, 7 d, 1 month, 3 months, and 6 months, respectively. There were no significant differences in IOP at different postoperative time points (F=9.58, P=0.006). Compared with preoperative levels, there were significant differences at every followup (P<0.05). Compared with preoperative measurements, the BCVA of 5 eyes improved. Conclusions: Intravitreal injection of conbercept combined with Ahemd glaucoma valve implants and panretinal photocoagulation is a safe and effective treatment for neovascular glaucoma.
|
Received: 11 April 2019
|
Corresponding Authors:
Danyu Gao, the Number 986 Hospital of the Air Force, Xi'an 710018, China (Email: gaodanyu723@sina.cn)
|
|
|
|
[1] |
Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol, 2016, 55: 196-204. DOI: 10.1159/000431196.
|
[2] |
Rodrigues GB, Abe RY, Zangalli C, et al. Neovascular glaucoma: A review. Int J Retina Vitreous, 2016, 2(1): 26-35. DOI: 10.1186/s40942-016-0051-x.
|
[3] |
Noma H, Mimura T, Yasuda K, et al. Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma. Ophthalmologica, 2014, 232(2): 102-109. DOI: 10.1159/000360303.
|
[4] |
Andrés-Guerrero V, Perucho-González L, García-Feijoo J, et al. Current perspectives on the Usue of anti-VEGF drugs as adjuvant therapy in glaucoma. Adv Ther, 2017, 34(2): 378-395. DOI: 10.1007/s12325-016-0461-z.
|
[5] |
史志洁, 张金嵩, 吕晓贝. 玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼. 眼科新进展, 2016, 36(8): 751-754. DOI: 10.13389/j.cnki.rao.2016.0200.
|
[6] |
Olmos LC, Sayed MS, Moraczewski AL, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond), 2016, 30(3): 463-472. DOI: 10.1038/eye.2015.259.
|
[7] |
周林, 黄素英, 李芳芳. 新生血管性青光眼联合治疗效果观察. 海南医学, 2017, 28(18): 3070-3073.
|
[8] |
冯桂强. 抗血管内皮生长因子在新生血管性青光眼治疗中的应用. 中华眼外伤职业眼病杂志, 2015, 37(3): 237-240. DOI: 10.3760/cma.j.issn.2095-1477.2015.03.021.
|
[9] |
文晓霞, 李红军, 谭德文, 等. 糖尿病视网膜病变玻璃体切割术前康柏西普玻璃体腔注射时机对VEGF表达水平和视力恢复的影响. 中华眼视光学与视觉科学杂志, 2019, 21(3): 181- 186. DOI: 10.3760/cma.j.issn.1674-845X.2019.03.005.
|
[10] |
黄晓菁, 谭烨, 陆士恒, 等. 玻璃体注射康柏西普联合减压阀植入治疗新生血管性青光眼的初步观察. 临床眼科杂志, 2017, 25(2): 162-164. DOI: 10.3969/j.issn.1006-8422.2017.02. 020.
|
[11] |
He Y, Tian Y, Song W, et al. Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article. Medicine (Baltimore), 2017, 96(42): e8350. DOI: 10.1097/MD. 0000000000008350.
|
[12] |
黄正如, 陈海英, 项晓丽, 等. 小梁切除术或Ahmed阀植入术治疗新生血管性青光眼的疗效分析. 中华眼视光学与视觉科学杂志, 2017, 19(10): 618-624. DOI: 10.3760/cma.j.issn.1674- 845X.2017.10.007.
|
[13] |
Netland PA, Ishida K, Boyle JW. The Ahmed Glaucoma Valve in patients with and without neovascular glaucoma. Journal of Glaucoma, 2010, 19(9): 581-586. DOI: 10.1097/ijg. 0b013e3181ca7f7f.
|
|
|
|